سعر اندوكسان 200مجم فيال للحقن الوريدي 2022

Cyclophosphamide 200 mg powder for solution for injection (vial) (Baxter Oncology Germany Endoxan; Egyptian distributor listed as Multipharma).

• History of severe hypersensitivity to cyclophosphamide, its metabolites or product components (anaphylaxis incl. death reported; cross-sensitivity with other alkylating agents possible); urinary outflow obstruction.General active-ingredient information · DailyMed (U.S. NLM)

• Myelosuppression, immunosuppression, bone marrow failure and serious/fatal infections (close hematologic monitoring); urinary tract and renal toxicity incl. hemorrhagic cystitis (ensure hydration, exclude obstruction); cardiotoxicity; pulmonary toxicity; secondary malignancies; veno-occlusive liver disease; infertility; embryo-fetal toxicity.General active-ingredient information · DailyMed (U.S. NLM)

• Protease inhibitorsMay increase cytotoxic metabolite concentrations and toxicities (infections, neutropenia, mucositis); monitor.DailyMed (U.S. NLM)
• Radiation therapy or drugs with similar toxicitiesMay potentiate cyclophosphamide toxicities; monitor.DailyMed (U.S. NLM)

• Can cause fetal harm: exposure may cause fetal malformations, miscarriage, fetal growth retardation and toxic effects in the newborn; advise of risk.General active-ingredient information · DailyMed (U.S. NLM)
• Present in breast milk; neutropenia, thrombocytopenia, low hemoglobin and diarrhea reported in breastfed infants; do not breastfeed during treatment and for 1 week after the last dose.General active-ingredient information · DailyMed (U.S. NLM)

• Close hematological monitoring (blood counts) during treatment; monitor for urinary tract toxicity and cardiac/pulmonary toxicity in at-risk patients.General active-ingredient information · DailyMed (U.S. NLM)

• Cyclophosphamide: Prodrug activated by hepatic metabolism to alkylating metabolites that cross-link DNA, interfering with cell division (alkylating drug per US label).